Lilly Presents First Clinical Data In Platinum-sensitive Ovarian Cancer For Its Investigational, Next-generation, FRα-targeting ADC At ESMO 2026
AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

Lilly reported Phase 1 results for investigational sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer: 23 of 29 patients with measurable disease had a confirmed response, and all 33 patients in the cohort had disease control. The results are preliminary; duration of response and progression-free survival medians had not been reached at the reported follow-up. The combination is being tested in Phase 3 trials.

Eli Lilly reported Phase 1 results for its investigational ovarian cancer drug sofetabart mipitecan, or Sofe-M, combined with bevacizumab, finding a confirmed response in 23 of 29 patients with measurable platinum-sensitive disease. The company said the 33-patient cohort had a 100% disease control rate; the findings are early clinical data, not evidence that the combination is an approved treatment or improves survival.

Before you orderOffer from Amazon

Get your next haul delivered free with Prime

  • Fast, free delivery on millions of items
  • Prime Video, Amazon Music and more included
  • Member-only deals all year
Start your free Prime trial Free trial for eligible customers · Cancel anytime
As an affiliate, we earn on qualifying purchases.

The cohort received Sofe-M at 4 mg/kg and bevacizumab at 15 mg/kg. Among the 29 patients with measurable disease, the confirmed objective response rate was 79.3% (23 of 29): six patients had a complete response and 17 had a partial response. Disease control, which includes responses and stable disease, was reported in all 33 women enrolled in the cohort.

Patients had received a median of three previous systemic regimens, with a range of one to six. Lilly said 67% had previously received a PARP inhibitor (PARPi) and 70% had received bevacizumab. It reported responses across FRα expression levels and among both patients previously treated with PARPi and those who had not. These are subgroup observations from a small Phase 1 cohort; the release does not provide subgroup counts or response estimates for each group.

At the July 6, 2026 data cutoff, median duration of response had not been reached after a median follow-up of 6.2 months, and median progression-free survival had not been reached after a median follow-up of 10.2 months. Lilly reported no new safety signals. Common treatment-emergent adverse events included nosebleeds and nausea, each in 73% of patients, anemia in 58%, neutropenia in 55% and fatigue in 52%. Grade 3 or higher neutropenia occurred in 42%, and anemia in 24%; 6% discontinued treatment because of an adverse event.

At a glance
announcementWhen: Announced ahead of an oral presentation…
The developmentLilly announced its first clinical data for sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer, reporting Phase 1 response and safety results.

A signal in PARPi-exposed disease

The findings matter because they offer an early look at a potential treatment approach for platinum-sensitive ovarian cancer, including patients previously exposed to PARP inhibitors. Lilly and the investigators point to that group as one where additional options are needed. Still, response rates from a small, non-comparative Phase 1 cohort cannot establish whether Sofe-M plus bevacizumab works better than existing care or how long any benefit lasts.

The safety results also inform the next stage of testing. While Lilly reported that only 6% stopped treatment because of an adverse event, dose reductions occurred in 42%, and serious blood-count-related toxicities were reported. Larger controlled trials will be needed to clarify the balance of benefit and risk.

Products Worth Considering

Oral-B iO3 Rechargeable Electric Toothbrush with 3 Cleaning Modes, Pressure Sensor, 2 Brush Heads and Travel Case, White

Oral-B iO3 Rechargeable Electric Toothbrush with 3 Cleaning Modes, Pressure Sensor, 2 Brush Heads and Travel Case, White

As an affiliate, we earn on qualifying purchases.

How the Phase 3 program is structured

Sofe-M is an investigational folate receptor alpha (FRα)-targeting antibody-drug conjugate. The antibody is designed to bind FRα on tumor cells and deliver exatecan, a topoisomerase I inhibitor, into those cells. Lilly describes FRα as commonly expressed in ovarian cancer. The Phase 1 study tested the combination in people with advanced solid tumors and included this 33-woman platinum-sensitive ovarian cancer cohort.

Lilly is studying Sofe-M in three global Phase 3 trials under its FRAmework-01 program. Part A tests the drug alone in platinum-resistant disease. Parts B and C test Sofe-M with bevacizumab in platinum-sensitive disease: Part B in patients whose cancer progressed on or within six months of completing a PARPi, and Part C in PARPi-naïve patients. The program involves international gynecologic oncology trial groups and the GOG Foundation.

“The durable and robust responses we’ve seen in patients with platinum-sensitive ovarian cancer are important, particularly in a PARPi pretreated population.”

— Chrisann Kyi, gynecologic medical oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center

Durability and comparative benefit remain unknown

The results come from a small Phase 1 cohort and were announced by Lilly ahead of an oral presentation at the 2026 ESMO Congress. The supplied report does not provide a comparison group, detailed patient-level results, or full statistical uncertainty estimates. It is not clear from these data whether the response rate will be reproduced in larger trials or translate into longer survival or improved quality of life.

Although median duration of response and progression-free survival were not reached at the stated follow-ups, that does not establish how long responses will last. Longer observation is needed. The source also does not provide detailed results for each FRα expression or PARPi-exposure subgroup, so the claim of similar activity across those groups cannot be independently evaluated from the figures given.

Phase 3 trials will test the combination

Lilly said Sofe-M is being evaluated in the FRAmework-01 Phase 3 trials, including two studies of the combination with bevacizumab in different platinum-sensitive, PARPi-defined populations. Those trials are expected to provide larger-scale evidence on efficacy and safety. The company’s announcement did not give enrollment targets, projected completion dates, or a timeline for results.

The next evidence to watch includes Phase 3 response and progression outcomes, longer follow-up on durability, and a fuller account of adverse events. Until those data are available and reviewed by regulators, Sofe-M remains investigational.

Key Questions

What did Lilly report for Sofe-M plus bevacizumab?

In a 33-patient Phase 1 cohort, Lilly reported disease control in all patients. Among the 29 with measurable disease, 23 had a confirmed response, for a 79.3% confirmed objective response rate.

Were the results the same for patients previously treated with PARP inhibitors?

Lilly said responses were observed in both PARPi-treated and PARPi-naïve patients and across FRα expression levels. The announcement did not provide detailed response figures for each subgroup, so the size and precision of those comparisons are unclear.

How long did responses last?

Median duration of response had not been reached at a median follow-up of 6.2 months. That means the available follow-up was not yet sufficient to calculate the median; it does not show how long responses will ultimately last.

Is Sofe-M approved for ovarian cancer?

No. Sofe-M is described by Lilly as an investigational drug. Its combination with bevacizumab is being studied in Phase 3 trials.

Source: primary

You May Also Like

Elliptical Stride Length and Why It Matters

Learn why adjusting your elliptical stride length matters for comfort, efficiency, and preventing injuries—discover how to optimize your workout today.

Play-Based Exercise: Fun Ways to Stay Active

Open your mind to the joy of play-based exercise and discover exciting ways to stay active that will transform your fitness routine.

Longevity Science: Lifestyle Tips for a Longer Life

Unlock the secrets to a longer life with essential lifestyle tips that could transform your health; discover what changes you can make today.

Financial Wellness Education: Money and Mental Health

Uncover the hidden link between financial wellness and mental health, and learn how mastering your money can transform your life.